List of good news of listed companies on December 24 (list attached)

A number of Listed Companies in Shanghai and Shenzhen issued important announcements on December 24. The following is a summary of good news:

Beijing Aosaikang Pharmaceutical Co.Ltd(002755) : the subsidiary tegacyclin for injection passed the conformity evaluation of generic drugs

Beijing Aosaikang Pharmaceutical Co.Ltd(002755) (002755) announced on December 24 that the wholly-owned subsidiary Jiangsu Beijing Aosaikang Pharmaceutical Co.Ltd(002755) recently received the notice of approval for supplementary application of drugs for tegacyclin for injection approved and issued by the State Food and drug administration, approving the drug to pass the consistency evaluation of quality and efficacy of generic drugs. Clinically, the drug is mainly used for the treatment of infection caused by sensitive strains of specific bacteria in patients over 18 years old: complex intraperitoneal infection, complex skin and soft tissue infection, community-acquired bacterial pneumonia.

Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) : pantoprazole sodium enteric coated tablets and cefprozil tablets passed the conformity evaluation of generic drugs

Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) (002793) it was announced on December 24 that Shandong Luoxin, a subsidiary of the company, recently received the notice of approval of drug supplementary application for pantoprazole sodium enteric coated tablets and the notice of approval of drug supplementary application for cefprozil tablets approved and issued by the State Food and drug administration. After review, the above two drugs passed the consistency evaluation of generic drug quality and efficacy.

Zhejiang Zhongxin Fluoride Materials Co.Ltd(002915) : the company resumed work and production on December 24

Zhejiang Zhongxin Fluoride Materials Co.Ltd(002915) (002915) announced on December 24 that at present, the company has met the requirements of the implementation opinions on orderly resumption of work and production of industrial enterprises in Shangyu district. After the application of the company and the approval of the local government, the company began to resume work and production in an orderly manner on December 24.

Shanghai Yuyuan Tourist Mart (Group) Co.Ltd(600655) : it is proposed to invest 490 million yuan to participate in the establishment of private equity investment fund

Shanghai Yuyuan Tourist Mart (Group) Co.Ltd(600655) (600655) announced on December 24 that the company plans to establish Fosun (Hangzhou) Hanxing private equity investment fund partnership (limited partnership) jointly with Fosun high tech and Hangzhou Gongshu Industrial Fund Co., Ltd. The total subscribed capital contribution of the fund is 1 billion yuan, of which 490 million yuan is contributed by the company’s subordinate enterprises as limited partners. Fosun high tech is the controlling shareholder of the company. The actual controller of the company and Fosun high tech is Guo Guangchang. This transaction constitutes a related party transaction.

Jiangsu Hengrui Medicine Co.Ltd(600276) : shr-1314 injection was approved for clinical trial

Jiangsu Hengrui Medicine Co.Ltd(600276) (600276) it was announced on December 24 that Suzhou shengdia biomedical Co., Ltd., a subsidiary of the company, received the notice of approval for clinical trial of shr-1314 injection approved and issued by the State Food and Drug Administration and will carry out clinical trial in the near future. The applied indication is adult active moderate to severe thyroid related ophthalmopathy.

Changzhou Qianhong Biopharma Co.Ltd(002550) : enoxaparin sodium injection passed the conformity evaluation of generic drugs

Changzhou Qianhong Biopharma Co.Ltd(002550) (002550) announced on December 24 that the company recently received the notice of approval for drug supplementary application for “enoxaparin sodium injection” approved and issued by the State Food and drug administration, approving the drug to pass the consistency evaluation of quality and efficacy of generic drugs.

Guizhou Salvage Pharmaceutical Co.Ltd(600227) : Acarbose Tablets obtained the drug registration certificate

Guizhou Salvage Pharmaceutical Co.Ltd(600227) (600227) announced on December 24 that on December 23, Guizhou Salvage Pharmaceutical Co.Ltd(600227) pharmaceutical, a wholly-owned subsidiary of the company, received the drug registration certificate approved and issued by the State Food and Drug Administration for the company’s drug Acarbose Tablets. Acarbose can effectively delay the hydrolysis of starch and other polysaccharides in the body, control postprandial blood glucose level and reduce the role of glycosylated hemoglobin, which is the largest selling variety of oral antidiabetic drugs in China.

Zhejiang Huangma Technology Co.Ltd(603181) : the company and its wholly-owned subsidiaries fully and orderly resume work and production

Zhejiang Huangma Technology Co.Ltd(603181) (603181) announced on December 24 that according to the implementation opinions on orderly resumption of work and production of industrial enterprises in Shangyu District issued by covid-19 epidemic prevention and control headquarters in Shangyu District, Shaoxing City on the afternoon of December 22, the company recently submitted a written application and resumption of work and production plan. After the territorial review and approval, the company and its wholly-owned subsidiary lvke’an company Real Madrid Shangyi company began to resume work and production comprehensively and orderly on December 24. As of the date of this announcement, the company’s inventory and production capacity can basically meet the requirements of the order delivery plan. The delivery period of some products has been appropriately adjusted, and the company’s undertaking of new orders has not been significantly affected. The covid-19 epidemic had no significant adverse impact on the company’s production and operation, and had little impact on the company’s overall performance in 2021.

Zhejiang Changhua Auto Parts Co.Ltd(605018) : the construction project of automobile stamping and welding parts (Wuhan) production base was officially put into operation

Zhejiang Changhua Auto Parts Co.Ltd(605018) (605018) announced on December 24 that the “automobile stamping and welding parts (Wuhan) production base construction project” is an investment project funded by the company’s initial public offering. It has officially entered the production stage, achieved mass production and supply, and completed the expected goal of putting into operation by the end of 2021.

Quantumctek Co.Ltd(688027) : signed a 40.49 million yuan quantum equipment and system procurement contract with Digital China Group Co.Ltd(000034)

Quantumctek Co.Ltd(688027) (688027) announced on December 24 that Beijing Quantumctek Co.Ltd(688027) Information Technology Co., Ltd., a wholly-owned subsidiary of the company, and Digital China Group Co.Ltd(000034) signed a sales contract for the procurement of quantum equipment and systems for the national wide area quantum secure communication backbone network construction project (Beijing to Harbin), with a contract amount of 40.4925 million yuan (including tax).

Tengda Construction Group Co.Ltd(600512) : won the bid for the 73.5059 million yuan new plant project

Tengda Construction Group Co.Ltd(600512) (600512) announced on December 24 that recently, the company received the letter of acceptance of construction project issued by Jiushan Village joint stock economic cooperative, Yucheng street, Yuhuan City, and determined that the company was the bid winner of the project of “new plant project in Jiushan small and micro enterprise park, Yucheng Street, Yuhuan City, Zhejiang Province”, with a bid winning amount of 73.5059 million yuan.

Shanghai Ceo Environmental Protection Technology Co.Ltd(688335) : some actual controllers, directors, supervisors and senior management plan to increase their holdings of the company’s shares by RMB 2.9 million-5.8 million

Shanghai Ceo Environmental Protection Technology Co.Ltd(688335) (688335) announced on December 24 that some actual controllers, directors, supervisors and senior managers of the company plan to increase their holdings of the company’s shares by means allowed by the system of Shanghai Stock Exchange (including but not limited to call auction, continuous bidding and block trading) within 6 months from December 27, 2021, with a total increase of no less than 2.9 million yuan and no more than 5.8 million yuan.

Inner Mongolia Eerduosi Resources Co.Ltd(600295) : the controlling shareholder and its persons acting in concert intend to increase their holdings of B-Shares of the company by US $10 million to US $10.1 million

Inner Mongolia Eerduosi Resources Co.Ltd(600295) (600295) announced on December 24 that the controlling shareholder of the company, Inner Mongolia Inner Mongolia Eerduosi Resources Co.Ltd(600295) Cashmere Group Co., Ltd., acting in concert, Hong Kong company, increased its B-Shares by 631500 shares on December 24, accounting for 0.0442% of the total share capital, and the transaction capital was us $1256600; The controlling shareholders and their persons acting in concert intend to increase their holdings of B-Shares of the company by US $10 million to US $10.1 million within 12 months, with an increase price of US $1.2 to US $2.2 per share.

Shanghai Qifan Cable Co.Ltd(605222) : some directors, supervisors and senior executives plan to increase their shares by 2 million yuan to 2.5 million yuan

Shanghai Qifan Cable Co.Ltd(605222) (605222) announced on December 24 that some directors, supervisors and senior managers plan to increase their holdings by 2-2.5 million yuan within one month at a price of no more than 30 yuan / share.

 

- Advertisment -